Comparison of the efficacy of Paliperidone and Aripiprazole in the treatment of schizophrenia
ZHANG Rui1 YANG Chun2▲#br#
1.Department of Military Psychiatric Medicine, the 904th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army, Jiangsu Province, Changzhou 213003, China;
2.the 904th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army Youth, Jiangsu Province, Changzhou 213003, China
Abstract:Objective To compare the efficacy of Paripipidone and Aripiprazole in the treatment of schizophrenia. Methods From November 2018 to October 2021, 102 patients with schizophrenia admitted to the the 904th Hospital of the Joint Logistics Support Force of the Liberation Army were randomly divided into Paliperidone group (treated with Paliperidone) and Aripiprazole group (treated with Aripiprazole), with 51 cases in each group. Patients of the two groups were evaluated for the treatment effect after three months of continuous treatment. The positive and negative symptom scale (PANSS) scores, clinical efficacy, neuromodulin 1 (NRG1), and neuron-specific enolase (NSE) levels were compared between the two groups. The adverse reactions during the treatment of the two groups were compared. Results There were significant differences in PANSS score betwee groups, time points, and interaction between groups (P < 0.05). Further pairwise comparison, intra group comparison: compared with before treatment, the PANSS scores of the two groups decreased after one month and three months of treatment (P < 0.05). Compared with one month after treatment, the PANSS scores of the two groups decreased after three months of treatment (P < 0.05). Comparison between groups: the PANSS scores of Paliperidone group after one month and three months of treatment were lower than those of Aripiprazole group (P < 0.05). The clinical effect of paripipidone group was better than Aripiprazole group (P < 0.05). After treatment, the levels of NRG1 in the two groups were higher than those before treatment, and the level of NRG1 in the Paliperidone group was higher than that in the Aripiprazole group (P < 0.05). After treatment, the NSE level of the two groups decreased, and the NSE level of the Paliperidone group was lower than that of the Aripiprazole group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P > 0.05). Conclusion Compared with Aripiprazole, Paliperidone in the treatment of schizophrenia can effectively relieve clinical symptoms, improve clinical efficacy, regulate serum neuregulin levels, and is safe and reliable.
张瑞1 杨春2▲. 帕利哌酮和阿立哌唑治疗精神分裂症患者的效果比较[J]. 中国医药导报, 2022, 19(22): 153-156.
ZHANG Rui1 YANG Chun2▲. Comparison of the efficacy of Paliperidone and Aripiprazole in the treatment of schizophrenia. 中国医药导报, 2022, 19(22): 153-156.